头孢他啶阿维巴坦与多黏菌素B治疗耐碳青霉烯类铜绿假单胞菌感染疗效比较  

Comparison of Efficacy of Ceftazidime/Averbactam and Polymyxin B in the Treatment of Carbapenem-Resistant Pseudomonas Aeruginosa Infection

作　　者：刘昌伟[1,2] 王小华 方玲[1,2] 陈强 胡立芬[1] LIU Changwei;WANG Xiaohua;FANG Ling;CHEN Qiang;HU Lifen(The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China 230022;The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine,Hefei Anhui,China 230022)

机构地区：[1]安徽医科大学第一附属医院,安徽合肥230022 [2]国家中医药管理局中药化学三级实验室,安徽合肥230022

出　　处：《中国药业》2024年第17期108-110,共3页China Pharmaceuticals

基　　金：2021年安徽省高校优秀青年人才支持计划项目[gxyq2021172]。

摘　　要：目的比较头孢他啶阿维巴坦(CAZ/AVI)与多黏菌素B(PMB)治疗耐碳青霉烯类铜绿假单胞菌(CRPA)感染的临床疗效。方法回顾性分析医院2019年1月至2022年12月收治的CRPA感染患者75例,按治疗方案的不同分为CAZ/AVI组(48例)和PMB组(27例),分别静脉滴注CAZ/AVI和PMB。结果CAZ/AVI组患者的临床治愈率、细菌清除率均显著高于PMB组(54.17%比29.63%,66.67%比37.04%,P<0.05),但皮肤色素沉着发生率显著低于PMB组(0比48.15%,P<0.001)。两组患者疗程、联合治疗及30 d死亡率均无显著差异(P>0.05)。结论CAZ/AVI治疗CRPA感染的临床疗效和细菌清除率均较PMB更高,且不良反应更少。Objective To compare the clinical efficacy of ceftazidime/averbactam(CAZ/AVI)and polymyxin B(PMB)in the treatment of carbapenem-resistant Pseudomonas aeruginosa(CRPA)infection.Methods A retrospective analysis was conducted on 75 patients with CRPA infection admitted to the hospital from January 2019 to December 2022.They were divided into the CAZ/AVI group(n=48)and the PMB group(n=27)according to different treatment plans.The patients in the CAZ/AVI group received intravenous infusion of CAZ/AVI,while the patients in the PMB group received intravenous infusion of PMB.Results The clinical cure rate and bacterial clearance rate in the CAZ/AVI group were significantly higher than those in the PMB group(54.17%vs.29.63%,66.67%vs.37.04%,P<0.05),but the incidence of skin pigmentation in the CAZ/AVI group was significantly lower than that in the PMB group(0 vs.48.15%,P<0.001).There was no significant difference in the course of treatment,combination therapy,and 30 d mortality rate between the two groups(P>0.05).Conclusion The clinical efficacy and bacterial clearance rate of CAZ/AVI in the treatment of CRPA infection patients are better than PMB,with fewer adverse reactions.

关 键 词：耐碳青霉烯类铜绿假单胞菌 头孢他啶阿维巴坦 多黏菌素B 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R978.1[医药卫生—药学]